0000950170-24-010460.txt : 20240202
0000950170-24-010460.hdr.sgml : 20240202
20240202160109
ACCESSION NUMBER: 0000950170-24-010460
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: de los Pinos Elisabet
CENTRAL INDEX KEY: 0001889633
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40971
FILM NUMBER: 24591218
MAIL ADDRESS:
STREET 1: C/O AURA BIOSCIENCES, INC.
STREET 2: 85 BOLTON STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aura Biosciences, Inc.
CENTRAL INDEX KEY: 0001501796
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 320271970
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 80 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 01235
BUSINESS PHONE: (617)500-8864
MAIL ADDRESS:
STREET 1: 80 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 01235
4
1
ownership.xml
4
X0508
4
2024-02-01
0001501796
Aura Biosciences, Inc.
AURA
0001889633
de los Pinos Elisabet
C/O AURA BIOSCIENCES, INC.
80 GUEST STREET
BOSTON
MA
01235
true
true
false
false
See Remarks
false
Common Stock
2024-02-01
4
A
false
162935
0.00
A
324373
D
Common Stock
131412
I
By EdIP Revocable Trust
Stock Option (Right to Buy)
7.77
2024-02-01
4
A
false
237065
0
A
2034-01-31
Common Stock
237065
237065
D
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2025, subject to the Reporting Person's continued service as of each such vesting date.
The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.
The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
President and Chief Executive Officer
/s/ Julie Feder, as Attorney-in-Fact
2024-02-02